ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2020

Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice

Francesca Cardwell1, Susan Elliott1, Megan R.W. Barber2, Kim Cheema2, Sydney George3, Adrian Boucher3 and Ann Clarke4, 1University of Waterloo, Waterloo, ON, Canada, 2University of Calgary, Calgary, AB, Canada, 3GlaxoSmithKline, Mississauga, ON, Canada, 4University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada

Meeting: ACR Convergence 2023

Keywords: Lupus nephritis, Qualitative Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: LN is a major cause of morbidity and mortality and develops in up to 60% of adult SLE patients. The experiences of patients with SLE have been explored quantitatively and qualitatively. However, we know little of the lived experiences of patients with LN. This research used a social constructionist perspective to explore patient experiences and perspectives of LN.

Methods: Patients aged≥18 years with biopsy-proven pure or mixed ISN/RPS Class III, IV, or V LN and fulfilling the ACR 1997 or SLICC 2012 Classification Criteria for SLE were purposefully recruited from a Canadian lupus cohort to participate in an innovative photovoice exercise. Over a 2-week period, participants took photos of what LN means to them, how LN impacts their daily life, and factors that impact how they manage their LN. Photos (3–5 participants) were shared and discussed in two virtual focus groups. Discussions were transcribed verbatim for subsequent thematic analysis using NVivo Software.

Results: Thirteen patients withLN participated; 92.3% were female, mean (SD) age was 41.7 (14.0) years (Table 1). Of the 54 photos, images depicting activities/settings that contribute to wellbeing (n=14), the participants themselves (n=13), healthcare experiences (n=10), home (n=5), work (n=2), community (n=2), friends (n=2), and other challenges (n=6) were shared (Table 2). All participants described the physical (e.g., fatigue, joint pain, rash) and psychosocial (e.g., fear, stress, social exclusion, feeling trapped, grief, and loss) impacts of living with LN. Although twelve discussed activities that contribute to well-being (e.g., listening to music, biking, walking dogs, spending time with family/friends, spending time in nature), participants were consistently reminded of their LN during/following these activities due to physical symptoms (There’d be days where my hands would cramp up and my knees would be stiff, but I just push through… because I love that experience of looking around at my surroundings, and the leaves falling (P5)), the need for caution while participating (I only rode [the bike] once, because I am always hearing my doctors very sage advice in my ear. Be careful, don’t overdo it (P3)), and altered life trajectories (My husband and I had envisioned we’d be playing with grandchildren… but I was never able to carry… [The dogs] are affectionate, loyal, and they need us… so they are sort of the light (P3); You’re always at a crossroad, you’re always having to make a decision… you have to turn left or right, you can’t keep going straight (P8)). Eleven participants discussed the need for, and burden of, medications to manage their LN; side effects (n=10) and medication-related financial challenges (n=5) were highlighted.

Conclusion: Respondents reported a substantial psychosocial burden associated with their LN diagnosis. While activities that contribute to well-being were emphasized, the physical, emotional, and lifestyle impacts of LN and the associated medication journey serve as frequent reminders of the disease burden, both now and into the future. The need for flexibility (i.e., from friends, employers, and themselves) is an essential component of navigating altered life trajectories.

Funding: GSK (GSK Study 218747)

Supporting image 1

Table 1. Patient Characteristics

Supporting image 2

Table 2. Results Overview


Disclosures: F. Cardwell: None; S. Elliott: None; M. Barber: AbbVie/Abbott, 2, AstraZeneca, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Sanofi-Genzyme, 2; K. Cheema: Alexion, 1, 6, Novartis, 1, Otsuka, 6; S. George: GlaxoSmithKlein(GSK), 3; A. Boucher: GlaxoSmithKlein(GSK), 3; A. Clarke: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, 5, Otsuka, 2, Roche, 2.

To cite this abstract in AMA style:

Cardwell F, Elliott S, Barber M, Cheema K, George S, Boucher A, Clarke A. Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/exploring-experiences-and-perspectives-of-canadian-patients-with-lupus-nephritis-through-photovoice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-experiences-and-perspectives-of-canadian-patients-with-lupus-nephritis-through-photovoice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology